v3.26.1
COMMON CONTROL MERGER (Tables)
6 Months Ended
Jun. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Nika BioTechnology, Inc Consolidated Financial Statement
Cash $ 322  
Inventory $ 17,007  
Accruals $ (3,833 )
Due to related parties $ (109,877 )
Additional paid in capital $ (5,388,284 )
Accumulated deficit $ 5,464,629  
General and administrative expenses $ 20,036